Infliximab is one of the first biological agents that has proven its efficacy in Crohn’s disease treatment in various multicenter randomized studies. Anticytokine treatment with infliximab allows to reach clinical, lab and endoscopic remission and secure its maintenance. This article contains clinical examples of anticytokine therpy with infliximab (Remikeid) efficacy in children with Crohn’s disease. Key words: Crohn’s disease, children, anticytokine therapy, infliximab. ( Voprosy sovremennoi pediatrii — Current Pediatrics. — 2011; 10 (5): 74–80.)
分享
引用
